Display Settings:

Format

Send to:

Choose Destination
    AIDS. 2008 Mar 12;22(5):653-5.

    Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.

    Source

    Indiana University School of Medicine, Indianapolis, Indiana, USA.

    Abstract

    We hypothesized that heightened systemic inflammation contributes to the increased rate of cardiovascular events in HIV-infected patients not receiving combination antiretroviral therapy. We performed a pilot trial to assess the effects of the nuclear factor-kappaB inhibitor salsalate on flow-mediated dilation of the brachial artery, a measure of endothelial function. Flow-mediated dilation significantly improved after 8 weeks of salsalate. However, hepatotoxicity occurred frequently. Research using alternative agents is warranted to examine the role of inflammation in HIV-related cardiovascular disease.

    PMID:
    18317009
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk